International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

Table 8 Descriptive statistics for aggregated company-level payments reported by JPMA member companies (2018)

	Minimum	Median (IQR) ($)	Maximum
All aggregated payments (category A, D, and E)
Value	0.0	6,346,032.8 (1,215,424.8– 17,573,059.3)	96,159,420.3
Share of all payments	0.0%	38.1% (29.1% – 49.1%)	83.1%
Aggregated non-R&D payments (category D and E)
Value	0.0	6,325,825.0 (1,001,734.5– 16,872,972.9)	96,096,014.5
Share of all payments	0%	36.5% (25.9%– 46.0%)	83.1%
Share of all aggregated payments	0%	99.9% (94.0%– 100%)	100%
Aggregated non-R&D payments to HCPs (category D)
Value	0.0	5,949,062.3 (879,128.7– 15,754,217.5)	94,574,275.4
Share of all payments	0%	34.5% (23.8%– 44.2%)	80.9%
Share of all aggregated non-R&D payments	0%	94.9% (91.2%– 97.9%)	100%
Aggregated non-R&D payments (category E)
Value	0.0	221,831.0 (24,419.9– 683,182.9)	3,456,984.4
Share of all payments	0.0%	1.4% (0.4% – 2.6%)	23.8%
Share of all aggregated non-R&D payments	0.0%	4.5% (2.0% – 8.6%)	100%
Aggregated R&D payments (category A)
Value	0.0	978.8 (0.0– 288,770.5)	7,237,318.8
Share of all payments	0.0%	0.0% (0.0%– 1.5%)	41.4%
Share of all aggregated payments	0.0%	0.1% (0.0%– 5.2%)	92.9%

Category A of R&D is further subdivided into separate detailed categories of public disclosures. Depending on the company, there was sometimes a mix of categories that were published with named information and categories that were published in aggregate. This table aggregates the latter
Category D is expenses related to information provision
Category E is defined as other non-R&D expenses that cannot be classified in any other category. It is described as including costs for hospitality as a social ritual
Aggregated payments Payments without named recipients, HCPs Healthcare professionals, HCOs Healthcare organisations, R&D Research and development

ISSN: 1744-8603